Specific genetic disorders and autism: Clinical contribution toward their identification

Service de Psychiatrie de l'Enfant et de l'Adolescent, Groupe Hospitalier Pitié-Salpétrière, Paris.
Journal of Autism and Developmental Disorders (Impact Factor: 3.34). 03/2005; 35(1):103-16. DOI: 10.1007/s10803-004-1038-2
Source: PubMed

ABSTRACT Autism is a heterogeneous disorder that can reveal a specific genetic disease. This paper describes several genetic diseases consistently associated with autism (fragile X, tuberous sclerosis, Angelman syndrome, duplication of 15q11-q13, Down syndrome, San Filippo syndrome, MECP2 related disorders, phenylketonuria, Smith-Magenis syndrome, 22q13 deletion, adenylosuccinate lyase deficiency, Cohen syndrome, and Smith-Lemli-Opitz syndrome) and proposes a consensual and economic diagnostic strategy to help practitioners to identify them. A rigorous initial clinical screening is presented to avoid unnecessary laboratory and imaging studies. Regarding psychiatric nosography, the concept of "syndromal autism"--autism associated with other clinical signs should be promoted because it may help to distinguish patients who warrant a multidisciplinary approach and further investigation.

Download full-text


Available from: Alain Verloes, Aug 17, 2015
1 Follower
  • Source
    • "Il semblerait que les différences entre le QI verbal et le QI performance diminuent lorsque le langage est préservé. D'autre part, il est important de noter que la présence de comorbidité est la règle dans le groupe TSA avec déficience intellectuelle (par exemple l'épilepsie [33]) confinant parfois à un tableau d'autisme syndromique [34]. Plusieurs déficits cognitifs spécifiques ont été associés aux TSA. "
    [Show abstract] [Hide abstract]
    ABSTRACT: La dystrophie myotonique de type 1 (DM 1) est une maladie neuromusculaire pouvant s’accompagner de troubles cognitifs et psychiatriques. Les études explorant ces aspects dans la forme infantile de la DM1 sont encore récentes et les données disponibles mettent en avant des résultats contradictoires, notamment en ce qui concerne la présence ou non de troubles du spectre autistique (TSA) dans cette population. La question d’une comorbidité entre la forme infantile de la DM1 et les TSA s’appuiera sur une revue de la littérature organisée selon deux axes : (1) une synthèse des travaux objectivant, d’une part, les troubles psychiatriques et cognitifs observés dans la DM1 mais aussi une analyse critique des études où la présence d’un TSA a été explorée dans cette même population et (2) une comparaison entre les profils cognitifs et le fonctionnement cérébral (données neuro-anatomiques et/ou neuro-fonctionnelles) de chacune de ces deux pathologies. La reconnaissance des signes cognitifs et psychiatriques spécifiques de la forme infanto-juvénile de la DM1, qu’ils comprennent ou non une dimension autistique propre, devrait constituer une étape fondamentale pour mieux guider les professionnels et améliorer la prise en charge.
    Neuropsychiatrie de l Enfance et de l Adolescence 12/2014; 63(2). DOI:10.1016/j.neurenf.2014.11.005
  • Source
    • "Additionally, 10–20% of FXS patients experience seizures (Incorpora et al., 2002; Hagerman and Stafstrom, 2009). Approximately 15–33% of individuals with FXS meet the three diagnostic criteria for autism, with approximately 5% of autism cases attributed to FXS (Bailey et al., 1998; Cohen et al., 2005). Consistent with autism spectrum disorder, many individuals with FXS display deficits in social behavior, repetitive behavior, and abnormalities in communication. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fragile X syndrome (FXS) is an inherited form of intellectual disability and autism. Among other symptoms, FXS patients demonstrate abnormalities in sensory processing and communication. Clinical, behavioral, and electrophysiological studies consistently show auditory hypersensitivity in humans with FXS. Consistent with observations in humans, the Fmr1 KO mouse model of FXS also shows evidence of altered auditory processing and communication deficiencies. A well-known and commonly used phenotype in pre-clinical studies of FXS is audiogenic seizures. In addition, increased acoustic startle response is seen in the Fmr1 KO mice. In vivo electrophysiological recordings indicate hyper-excitable responses, broader frequency tuning, and abnormal spectrotemporal processing in primary auditory cortex of Fmr1 KO mice. Thus, auditory hyper-excitability is a robust, reliable, and translatable biomarker in Fmr1 KO mice. Abnormal auditory evoked responses have been used as outcome measures to test therapeutics in FXS patients. Given that similarly abnormal responses are present in Fmr1 KO mice suggests that cellular mechanisms can be addressed. Sensory cortical deficits are relatively more tractable from a mechanistic perspective than more complex social behaviors that are typically studied in autism and FXS. The focus of this review is to bring together clinical, functional, and structural studies in humans with electrophysiological and behavioral studies in mice to make the case that auditory hypersensitivity provides a unique opportunity to integrate molecular, cellular, circuit level studies with behavioral outcomes in the search for therapeutics for FXS and other autism spectrum disorders.
    Frontiers in Cellular Neuroscience 02/2014; 8:19. DOI:10.3389/fncel.2014.00019 · 4.18 Impact Factor
  • Source
    • "Their behaviour was considered to be autistic-type in terms of deficits in social relatedness, impaired communication and repetitive behaviours. In case a specific genetic syndrome was diagnosed, we used 'syndromic autism' (Cohen et al. 2005 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background  In some of our patients with intellectual disabilities (ID) and sleep problems, the initial good response to melatonin disappeared within a few weeks after starting treatment. In these patients melatonin levels at noon were extremely high (>50 pg/ml). We hypothesise that the disappearing effectiveness is associated with slow metabolisation of melatonin because of a single nucleotide polymorphism (SNP) of CYP1A2. Method  In this pilot study we analysed DNA extracted from saliva samples of 15 consecutive patients with disappearing effectiveness of melatonin. Saliva was collected at noon and 4 pm for measuring melatonin levels. Results  In all patients' salivary melatonin levels at noon were >50 or melatonin half time was >5 h. A SNP was found in eight of 15 patients. The allele *1C was found in two patients and in six patients the *1F allele was found. Conclusions  Of 15 patients with disappearing effectiveness of melatonin, seven were diagnosed with autism spectrum disorder, and in four of them a SNP was found. The other eight patients were known with a genetic syndrome. In six of them behaviour was considered to be autistic-type and in three of them a SNP was found. This finding may give a new direction for research into the genetic background of autism.
    Journal of Intellectual Disability Research 07/2012; 57(11). DOI:10.1111/j.1365-2788.2012.01595.x · 2.41 Impact Factor
Show more